Retrospective, non-interventional, longitudinal, multi-cohort/parallel group study to assess the safety, tolerability, and efficacy of analgesic therapy with cannabinoids vs. non-cannabinoids in CKD patients with peripheral neuropathic pain/muscle pain depending on the degree of renal impairment (ICD10: N18.1-5) using depersonalized 6-month data from the German Pain e-Registry (CANRELIEF)

Study identification

• EU PAS number:
  EUPAS1000000738
• Study ID:
  1000000738
• Official title and acronym:
  Retrospective, non-interventional, longitudinal, multi-cohort/parallel group study to assess the safety, tolerability, and efficacy of analgesic therapy with cannabinoids vs. non-cannabinoids in CKD patients with peripheral neuropathic pain/muscle pain depending on the degree of renal impairment (ICD10: N18.1-5) using depersonalized 6-month data from the German Pain e-Registry (CANRELIEF)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  CANRELIEF is a non-interventional, retrospective analysis of anonymized data from the German Pain E-Register, in which routine data from daily care are used to evaluate the efficacy and tolerability of cannabis-based pain medications compared to approved standard analgesics and co-analgesics in adults with chronic kidney dysfunction.; The main feature of the treatment documentation is the prescription of various active ingredients for pain treatment within the framework of the applicable national laws and prescription options in Germany (including the Act Amending the Narcotics Act and Other Regulations (§ 31 (6) SGB V) and the use of the online documentation software iDocLive® for standardized observation of the course of treatment in accordance with the usual standards of care over a period of at least 6 months.
• Study status:
  Finalised

Research institutions and networks

Institutions

O.Meany-MDPM

Study timelines

Date when funding contract was signed

Planned:05/06/2025

Actual:05/06/2025

Study start date

Planned:06/06/2025

Actual:06/06/2025

Data analysis start date

Planned:01/07/2025

Actual:01/07/2025

Date of interim report, if expected

Planned:02/09/2025

Actual:02/09/2025

Date of final study report

Planned:30/09/2025

Actual:09/09/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

IFNAP
private Institute of Neurological Sciences
Nordostpark 51
90411 Nürnberg

STADAPHARM GmbH
Stadastraße 2-18
61118 Bad Vilbel
Deutschland

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable